Travere Therapeutics (TVTX) EV to CFO (2012 - 2026)
Travere Therapeutics' (TVTX) EV to CFO was 56.44 for Q2 2026, down 16.2% from the prior quarter.
Powered by 
Analysis
Travere Therapeutics (TVTX) EV to CFO (2012 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Travere Therapeutics' EV to CFO came in at 53.40; for FY2025, it was 89.49.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.90 Bn | 1,105.48 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.06 Bn | 535.59 Bn | 17.26 Bn |
| 3 | AbbVie | 501.38 Bn | 474.49 Bn | 12.70 Bn |
| 4 | Merck | 367.41 Bn | 321.79 Bn | 12.21 Bn |
| 5 | Novartis Ag | 297.92 Bn | 261.91 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.31 Bn | 235.00 Bn | 12.86 Bn |
| 7 | Amgen | 236.29 Bn | 191.69 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 190.40 Bn | 164.60 Bn | 6.22 Bn |
| 9 | Pfizer | 169.55 Bn | 116.19 Bn | 10.94 Bn |
| 10 | Travere Therapeutics | 4.96 Bn | 4.56 Bn | 167.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.44 |
| Mar 31, 2026 | 67.33 |
| Dec 31, 2025 | 89.49 |
| Dec 31, 2017 | 71.45 |
| Sep 30, 2016 | 379.67 |
| Mar 31, 2016 | 169.42 |
| Dec 31, 2012 | 21.33 |
API Access
Travere Therapeutics EV to CFO API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=TVTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-cfo", "ticker": "TVTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=TVTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();